Roughly half as many patients with cirrhosis in remission from overt hepatic encephalopathy (OHE) experienced a breakthrough ...

For patients with a history of overt hepatic encephalopathy (OHE), rifaximin monotherapy (MT) results in significantly fewer ...

For patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt (TIPS) placement, rifaximin used before and after the procedure is associated with a reduced risk for overt ...

The antibiotic, rifaximin, has enabled the global emergence of vancomycin-resistant enterococcus faecium, or VRE, a superbug that frequently causes serious infections in hospitalised patients ...

(NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced that results of an analysis of Xifaxan® (rifaximin) monotherapy will be presented during a ...

LAVAL, QC / ACCESSWIRE / October 27, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals (“Salix”), announced that results of an ...

The annual meeting of the American College of Gastroenterology was held from Oct. 25 to 30 in Philadelphia and attracted ...

But when exposed to rifaximin, the VRE bacteria don't just get one boost – they gain multiple abilities, like super-speed and super-strength, allowing them to easily defeat even the final boss ...

A new study has found that an antibiotic for liver disease patients could expose them to greater risk of a dangerous superbug. The international team of researchers found that an antibiotic ...